Lindsay Fischer

The real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Concurrent treatment with intravenous vitamin C and chemotherapy may benefit cisplatin-ineligible patients with locally advanced muscle-invasive bladder cancer.

Immune-related adverse events may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab in patients with metastatic urothelial carcinoma.

Urine cytology specimen NGS was found to be a feasible and valid method of assessing genomic alterations in patients with upper tract urothelial carcinoma.

A secondary analysis of 2 treatment alteration studies demonstrated that 18F-fluciclovine PET/CT scans play a pivotal role in determining if androgen deprivation therapy is appropriate for patients with prostate cancer.

“Understanding the burden and time course of adverse events commonly associated with ARIs that may impact patients’ daily life will help inform optimal treatment selection for men with nmCRPC,” explained Christian Gratzke, MD.